Close filter

Ben Maddox

Contact Details

+44 207 943 5817

Connect With Me

Ben Maddox is active globally in Egon Zehnder’s Health Practice. He is an experienced strategic advisor with specialized expertise in pharma, biotech, and life sciences, with a passion for the benefits that science and innovation can bring to patients. Ben leads Executive and Board searches, as well as providing assessment and development support for senior leaders. He has a particular interest in C-suite and R&D leadership roles.

People are at the core of the health sector, both as patients and as leaders. I am energized by finding and developing the best leaders and enabling them to bring exciting scientific innovations to market.

Prior to joining Egon Zehnder, Ben was a Principal at IQVIA. At IQVIA he led the Cambridge, UK office and advised international pharma, biotech, and medical device clients on a wide range of business issues, including pricing and market access, clinical evidence generation, and brand strategy.

He holds a PhD in biochemistry and Masters in Natural Sciences from the University of Cambridge. Ben still lives in Cambridge with his wife and young daughters. Outside of work he enjoys spending time tinkering with technology.

Get in touch
Send Ben a Message
Browse all
Thought Leadership

Thought Leadership by Ben Maddox

Confronting the Challenge of Attracting and Retaining African Scientists to the Continent

Confronting the Challenge of Attracting and Retaining African Scientists to the Continent

Egon Zehnder partnered with the UK Medical Research Council to interview 15 African biomedical scientists and ask why they work elsewhere. Read more

EU Biotech CEOs and Board Members Reflect on a Turbulent 2020

EU Biotech CEOs and Board Members Reflect on a Turbulent 2020

Egon Zehnder rounded off 2020 with a final gathering of biotech CEOs and board members, who shared their reflections on a turbulent year. Read more

In for the Long Haul: Biotechs Address the Issues Presented by the Extended Pandemic

In for the Long Haul: Biotechs Address the Issues Presented by the Extended Pandemic

Evolving personal work patterns are demonstrating people’s amazing adaptability in the face of the pandemic. Read more

Biotech During a Pandemic: Addressing Challenges Along the Pharma Value Chain

Biotech During a Pandemic: Addressing Challenges Along the Pharma Value Chain

European Biotech leaders reveal to Egon Zehnder that people are becoming much more comfortable and efficient at using virtual meetings. Read more

European Biotech CEOs Navigate Towards a “New Normal

European Biotech CEOs Navigate Towards a “New Normal" Pt 2

Highlights from the fourth round of digital gatherings with European Biotech CEOs, hosted by Egon Zehnder. Read more

Coronavirus – Learnings and Takeaways from Small Biotech

Coronavirus – Learnings and Takeaways from Small Biotech

Highlights from the second round of digital gatherings with European Biotech CEOs, hosted by Egon Zehnder. Read more

European Biotech CEOs Navigate Towards a “New Normal” Pt 1

European Biotech CEOs Navigate Towards a “New Normal” Pt 1

Highlights from the third round of digital gatherings with European Biotech CEOs, hosted by Egon Zehnder. Read more

Related Experts Around the Globe

Michele Moncrief

Michele Moncrief

Houston

Michele Moncrief, based in Houston, is a trusted advisor to clients on leadership assessment and development as well as board and executive search. Read more

Juliana Rodríguez

Juliana Rodríguez

Bogotá

Juliana Rodríguez Caicedo, based in Bogotá, serves clients across Latin America as an active member of Egon Zehnder’s Financial Services and Consumer… Read more

Steven Goodman

Steven Goodman

Houston

Steve Goodman is Egon Zehnder’s Managing Partner in Houston and previously led the North American Energy Practice. Today, he advises clients across… Read more

Changing language
Close icon

You are switching to an alternate language version of the Egon Zehnder website. The page you are currently on does not have a translated version. If you continue, you will be taken to the alternate language home page.

Continue to the website

Back to top